202 related articles for article (PubMed ID: 36197842)
1. Preparation,
Barta P; Kamaraj R; Kucharova M; Novy Z; Petrik M; Bendova K; Hajduch M; Pavek P; Trejtnar F
Bioconjug Chem; 2022 Oct; 33(10):1825-1836. PubMed ID: 36197842
[TBL] [Abstract][Full Text] [Related]
2. ⁶⁸Ga-NODAGA-VEGF₁₂₁ for in vivo imaging of VEGF receptor expression.
Kang CM; Koo HJ; Choe YS; Choi JY; Lee KH; Kim BT
Nucl Med Biol; 2014 Jan; 41(1):51-7. PubMed ID: 24183611
[TBL] [Abstract][Full Text] [Related]
3. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.
Kang CM; Kim SM; Koo HJ; Yim MS; Lee KH; Ryu EK; Choe YS
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):198-206. PubMed ID: 23096079
[TBL] [Abstract][Full Text] [Related]
6. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
8. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
10. In vivo preclinical evaluation of the new
Trencsényi G; Kis A; Szabó JP; Ráti Á; Csige K; Fenyvesi É; Szente L; Malanga M; Méhes G; Emri M; Kertész I; Vecsernyés M; Fenyvesi F; Hajdu I
Int J Pharm; 2020 Feb; 576():118954. PubMed ID: 31935470
[TBL] [Abstract][Full Text] [Related]
11. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
12. Radiochemical synthesis and preclinical evaluation of
Hajdu I; Angyal J; Szikra D; Kertész I; Malanga M; Fenyvesi É; Szente L; Vecsernyés M; Bácskay I; Váradi J; Fehér P; Ujhelyi Z; Vasvári G; Rusznyák Á; Trencsényi G; Fenyvesi F
Eur J Pharm Sci; 2019 Feb; 128():202-208. PubMed ID: 30521943
[TBL] [Abstract][Full Text] [Related]
13. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
16. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
17. Radiosynthesis, Biological Evaluation, and Preclinical Study of a
Pirooznia N; Abdi K; Beiki D; Emami F; Arab SS; Sabzevari O; Pakdin-Parizi Z; Geramifar P
Contrast Media Mol Imaging; 2020; 2020():8421657. PubMed ID: 32292304
[TBL] [Abstract][Full Text] [Related]
18.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
19. Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.
Chakraborty S; Chakravarty R; Vatsa R; Bhusari P; Sarma HD; Shukla J; Mittal BR; Dash A
Nucl Med Biol; 2016 Jan; 43(1):116-123. PubMed ID: 26527030
[TBL] [Abstract][Full Text] [Related]
20. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
